Over the last three months, Editas Medicine (EDIT) has been a top loser in the biotechnology industry, falling by 18.5% to $8.37 per share. This information was gathered by A.I.dvisor, which analyzed 968 stocks in the biotechnology industry for the 3-month period ending March 17, 2023, and found that 60.19% of them demonstrated a downtrend, while only 39.81% exhibited an uptrend.
However, there is some positive news for EDIT as it is currently in an upward trend. The price of EDIT may ascend as a result of having broken its lower Bollinger Band on March 10, 2023. This means that EDIT may jump back above the lower band and head towards the middle band. Traders may consider buying the stock or exploring call options.
It is interesting to note that in 29 out of 32 cases where EDIT's price broke its lower Bollinger Band, its price rose further in the following month. This means that the odds of a continued upward trend are quite high, at 90%.
Despite EDIT's recent losses, the company's potential to impact the biotechnology industry is significant. Editas Medicine is a leading genome editing company that uses CRISPR technology to develop new therapies for genetic diseases. The company's pipeline includes treatments for a range of diseases, including sickle cell anemia, beta-thalassemia, and Duchenne muscular dystrophy.
In addition to its pipeline, Editas Medicine has partnerships with major pharmaceutical companies such as Allergan and Juno Therapeutics. These partnerships help to provide the company with funding and resources to continue its research and development efforts.
Overall, while EDIT may have experienced losses over the last three months, the company's potential for growth is significant.
The Moving Average Convergence Divergence (MACD) for EDIT turned positive on July 02, 2025. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in of 237 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 134 cases where EDIT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for EDIT moved out of overbought territory on July 11, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
EDIT broke above its upper Bollinger Band on July 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EDIT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.823) is normal, around the industry mean (17.480). P/E Ratio (0.000) is within average values for comparable stocks, (59.327). EDIT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.459). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (6.570) is also within normal values, averaging (273.307).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company which translates genome editing technology into a novel class of human therapeutics
Industry Biotechnology